ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Manhattan Scientifics (OTCQB:MHTX) announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Ms. Upham’s role will be to identify initial markets and facilitate relationships with strategic partners for the company.
“We are involved in early collaborative planning with the U.S.'s No. 1 cancer research hospital because of our company’s ability to find cancers years before other known methods.”
Loraine Upham has over 30 years of biotechnology commercialization experience. She is best known for her co-invention and development of a novel treatment for diabetes that was partnered in a $335M deal with Sanofi-Aventis in 2010.
Ms. Upham said, “It is an honor to work with Dr. Flynn and the Senior Scientific team led by its president Gerald Grafe. This company has terrific potential to impact markets in a number of sectors through strategic partnerships. The technology is extraordinary and can be applied to everything from drug discovery and development and in vitro diagnostics to in vivo animal imaging and quantification, while human clinical applications are established.”
Senior Scientific, a unit of Manhattan Scientifics Inc., is pioneering the technology, driving it from “bench to bedside”. The technology uses non-toxic iron oxide nanoparticles and ultrasensitive magnetic detection for a highly sensitive and very specific approach to cancer detection that can locate and measure tumors one millionth the size detectable by X-Rays and MRI.
Marvin Maslow, Manhattan Scientifics' founder said, "We are involved in early collaborative planning with the U.S.'s No. 1 cancer research hospital because of our company’s ability to find cancers years before other known methods.”
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.